Clinical Study On Treatment Of Slow Flow Phenomenon With Dipyridamole

Objective:This essay investigates the pathogenesis of coronary slow flow phenomenon through clinical studies of dipyridamole treatment of coronary slow flow phenomenon. It also assesses the coronary slow flow phenomenon prognosis for medical intervention in patients with coronary slow flow, evaluates the effect of the dipyridamole in the treatment of coronary slow flow and determines whether it makes sense for medical intervention in patients with coronary slow flow. Method:Select35patients who came to our hospital from2009to2011and was diagnosed coronary slow flow phenomenon accordance with the inclusion criteria. Respectively collect their general information, CTFC values and The Seattle angina score. After that, give them aspirin100mg Qd, oral dipyridamole50mg Tid. At the same time, we make telephone follow-up of all patients after treatment (once a month), observe within6months of symptoms and the incidence and register it. six months after the medication review Coronary angiography CTFC, analysis the records of the three coronary and do symptom score of The Seattle Angina Scale again. Compare whether there is Medicine statistical significances of the coronary slow flow patients’three coronary CTFC value and the Seattle Angina score changes before and after the intervention.(p<0.05there is statistical difference)Result:Patients with coronary slow flow occurs mostly in middle-aged male who have the bad habits of smoking. Two cases of35patients in the study still had the intermittent chest pain, eight cases still had the intermittent chest tightness symptoms, one case appeared chest pain with ECG changes and one cases had a sudden death. There are statistical difference when compare the score of patients with coronary slow flow of three coronary CTFC value and The Seattle Angina (p<0.05there is statistical difference). Result:Coronary slow flow seems to occur in smoking-addicted middle-aged male; smoking may be risk factors for coronary slow flow phenomenon; The coronary slow flow phenomenon does not seem to be functional disease, may be more like the organic disease; the coronary slow flow phenomenon is not seem to be age-related degenerative diseases of the vascular, more like a disease has a clear role of pathophysiological mechanisms and psychosocial mechanisms; the coronary slow flow patient’s blood pressure, heart rate reserve capacity may decline; slow coronary blood flow in patients with coronary artery seems to the "potential" of coronary artery, is a "castrated version" of the coronary artery, may be the exception on the functional anatomy; the coronary microcirculation is the primary coronary slow flow phenomenon pathogenesis theory seems to have a greater rationality; dipyridamole in the treatment of coronary slow flow patients seem to actually improves some patients with coronary artery CTFC values and the Seattle angina score; slow coronary blood flow in patients with appropriate medical intervention seems to be necessary.